

CITATION REPORT

List of articles citing

Treatment with sildenafil for the healing of refractory skin ulcerations in the antiphospholipid syndrome

DOI: 10.1191/0961203303lu257cr
Lupus, 2003, 12, 133-5.

Source: <https://exaly.com/paper-pdf/35863288/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
37	[Medicinal vasoactive therapy of microcirculation disorders in rheumatoid arthritis]. <i>Zeitschrift Fur Rheumatologie</i> , 2005 , 64, 123-36	1.9	2
36	Skin Manifestations of Antiphospholipid Syndrome. 2006 , 86-98		2
35	Dermatologic aspects of Antiphospholipid Antibody Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2006 , 103-117	0.3	1
34	Hughes Syndrome. 2006 ,		5
33	Oral phosphodiesterase type 5 inhibitors: nonerectogenic beneficial uses. <i>Journal of Sexual Medicine</i> , 2008 , 5, 2502-18	1.1	37
32	Viagra and wound healing: the NO connection. <i>Advances in Skin and Wound Care</i> , 2008 , 21, 106, 108-9	1.5	13
31	PDE5 inhibitors in non-urological conditions. <i>Current Pharmaceutical Design</i> , 2009 , 15, 3521-39	3.3	24
30	From cellulite to smooth skin: is Viagra the new dream cream?. <i>Medical Hypotheses</i> , 2009 , 73, 118-9	3.8	11
29	Chapter 18 Difficult Clinical Situations in the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2009 , 10, 215-234	0.3	
28	Non-criteria manifestations of antiphospholipid syndrome. <i>Lupus</i> , 2010 , 19, 424-7	2.6	49
27	Dermatological manifestations of Hughes' antiphospholipid antibody syndrome. <i>Lupus</i> , 2010 , 19, 1071-72.6		35
26	Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 2297-313	4	12
25	Retiform purpura and digital gangrene secondary to antiphospholipid syndrome successfully treated with sildenafil. <i>Archives of Dermatology</i> , 2011 , 147, 164-7		9
24	[Dermatologic manifestations of the antiphospholipid syndrome]. <i>Revue De Medecine Interne</i> , 2012 , 33, 200-5	0.1	9
23	An old drug for a new application: potential benefits of sildenafil in wound healing. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2012 , 15, 483-98	3.4	13
22	Complex Raynaud's phenomenon: evolving concepts of management. <i>International Journal of Clinical Rheumatology</i> , 2013 , 8, 689-706	1.5	
21	[Sildenafil in chronic cutaneous ulcers refractory to other treatments]. <i>Medicina Clínica</i> , 2013 , 140, 332-31		

20	Skin involvement in cutaneous and systemic vasculitis. <i>Autoimmunity Reviews</i> , 2013 , 12, 467-76	13.6	70
19	Title efficacy of phosphodiesterase 5 inhibitor on distant burn-induced muscle autophagy, microcirculation, and survival rate. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013 , 304, E922-33	6	23
18	Effect of sildenafil citrate on secondary healing in full thickness skin defects in experiment. <i>Bratislava Medical Journal</i> , 2014 , 115, 267-71	1.7	4
17	Leg ulcers in antiphospholipid syndrome secondary to systemic lupus erythematosus treated with intravenous immunoglobulin. <i>Journal of Dermatological Case Reports</i> , 2014 , 8, 38-41		1
16	Tadalafil therapy and severe chronic foot wound resolution. <i>International Wound Journal</i> , 2015 , 12, 733-6.6		3
15	Difficult clinical situations in the antiphospholipid syndrome. <i>Current Rheumatology Reports</i> , 2015 , 17, 29	4.9	13
14	Antiphospholipid Syndrome. 2017 ,		3
13	Fast Cicatrization of Extensive Livedoid Vasculopathy Ulcers under Treatment with Sildenafil. <i>Annals of Dermatology</i> , 2017 , 29, 125-127	0.4	1
12	Phosphodiesterase type 5 and cancers: progress and challenges. <i>Oncotarget</i> , 2017 , 8, 99179-99202	3.3	28
11	Contact Dermatitis due to Lubricant Oils in a Brass Musician. <i>Annals of Dermatology</i> , 2017 , 29, 127-129	0.4	1
10	Extensive abdominal wall ulceration as a late manifestation of antiphospholipid syndrome: a case report. <i>Journal of Medical Case Reports</i> , 2018 , 12, 226	1.2	4
9	Effect of tadalafil on reduction of necrosis in the ischemic zone in a rat comb burn model. <i>Burns</i> , 2018 , 44, 1427-1432	2.3	9
8	The effect of tadalafil on reepithelialization and scarring of partial thickness porcine burns. <i>Wound Repair and Regeneration</i> , 2020 , 28, 26-32	3.6	5
7	Management of anticoagulant-refractory thrombotic antiphospholipid syndrome. <i>Lancet Haematology,the</i> , 2020 , 7, e613-e623	14.6	4
6	Myeloid-Derived Suppressor Cells as Target of Phosphodiesterase-5 Inhibitors in Host-Directed Therapeutics for Tuberculosis. <i>Frontiers in Immunology</i> , 2020 , 11, 451	8.4	11
5	Vasoactive and Antiplatelet Agents. 2021 , 358-365.e3		1
4	Treatment of Non-criteria Manifestations in Antiphospholipid Syndrome. 2017 , 247-266		4
3	Manifestaões crííico e nã crííico na síndrome antifosfolípide. <i>Revista Paulista De Reumatologia</i> , 2018 , 7-11	0.1	

2 Vasoactive and antiplatelet agents. **2013**, 353-360.e3

1 Sildenafil, a Type-5 Phosphodiesterase Inhibitor, Fails to Reverse Myeloid-Derived Suppressor Cell-Mediated T Cell Suppression in Cells Isolated From Tuberculosis Patients. 13,

○